BCRX
BioCryst Pharmaceuticals, Inc.
BCRX has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has slightly lower modeled downside risk, despite its lower overall score.
BCRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Strong | |
| Strong |
BCRX's revenue, cash flow and balance sheet are currently healthy, but its profitability is weak.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
BCRX PE Valuation
BCRX has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
BCRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
BCRX has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
BCRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.66 | — |
| Q3 2026 | -$1.41 | -$1.36 |
| Q2 2026 | -$1.49 | -$1.31 |
| Q1 2026 | -$1.77 | -$1.51 |
| Q4 2025 | $1.21 | +$1.64 |
| Q3 2025 | -$0.05 | +$0.56 |
| Q2 2025 | -$0.18 | +$0.55 |
| Q1 2025 | -$0.26 | +$0.81 |
| Q4 2024 | -$0.43 | +$0.75 |
BCRX lost $1.41 per share over the past year, a bigger loss than the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over BCRX on earnings quality, reporting a profit while its opponent remains loss making.
BCRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $180.3M | +13% |
| Q2 2026 | $218.3M | +34% |
| Q1 2026 | $156.4M | +7.5% |
| Q4 2025 | $406.6M | +209% |
| Q3 2025 | $159.4M | +36% |
| Q2 2025 | $163.4M | +49% |
| Q1 2025 | $145.5M | +57% |
| Q4 2024 | $131.5M | +41% |
BCRX has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | +11 points |
| Q2 2026 | 45% | +27 points |
| Q1 2026 | -449% | -463 points |
| Q4 2025 | 64% | +68 points |
| Q3 2025 | 19% | +12 points |
| Q2 2025 | 18% | +10 points |
| Q1 2025 | 15% | +30 points |
| Q4 2024 | -3.4% | +42 points |
BCRX's operating margin was 30% last quarter, up 11 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over BCRX on profitability, with a higher operating margin.
BCRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $32.8M | -19% |
| Q2 2026 | $104.1M | +153% |
| Q1 2026 | -$62.2M | -$34.5M |
| Q4 2025 | $291.2M | +$297M |
| Q3 2025 | $40.3M | +392% |
| Q2 2025 | $41.1M | +$42.6M |
| Q1 2025 | -$27.7M | +$26.3M |
| Q4 2024 | -$5.9M | +$3.6M |
BCRX has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
BCRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.5M shares |
| 1 year | +22% | +47.7M shares |
| 3 years | +41% | +78M shares |
| 5 years | +51% | +90.3M shares |
| Available history | +74% | +113M shares |
BCRX has 268M diluted shares, up 22% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over BCRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
BCRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 2.8x | Moderate |
| Q1 2025 | 6.1x | High |
BCRX has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
BCRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.7 | Neutral |
| Stochastic | 16.2 | Oversold |
BCRX's weekly RSI is 43 (neutral) and its Stochastic is 16 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
BCRX PE vs Healthcare Sector
BCRX has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BCRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.07 | 4.8% below |
| 20 week MA | $8.89 | 14% below |
| 50 week MA | $8.50 | 9.6% below |
| 100 week MA | $8.38 | 8.4% below |
| 200 week MA | $7.71 | 0.4% below |
BCRX is in a downtrend: it's below all five of its weekly moving averages, and 0.4% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over BCRX on trend strength, trading above more of its moving averages.
BCRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.12 | $7.28 | +133% |
| 2021 | $7.28 | $13.9 | +91% |
| 2022 | $13.9 | $11.5 | -18% |
| 2023 | $11.5 | $5.99 | -48% |
| 2024 | $5.99 | $7.71 | +29% |
| 2025 | $7.71 | $7.63 | -1% |
| 2026 YTD | $7.63 | $7.68 | +0.7% |
BCRX has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.